Metabolie syndrome and liver transplantation

Panminerva Medica

Volumn 51, Issue 4, 2009, Pages 205-213

  Kadayifci, A ^a  

^a GAZIANTEP UNIVERSITY   (Turkey)

Author keywords

Fatty liver; Liver transplantation; Metabolic syndrome x

Indexed keywords

CARDIOVASCULAR DISEASE; FATTY LIVER; GRAFT SURVIVAL; HUMAN; LIVER FAILURE; LIVER TRANSPLANTATION; METABOLIC SYNDROME X; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

CARDIOVASCULAR DISEASES; FATTY LIVER; GRAFT SURVIVAL; HUMANS; LIVER FAILURE; LIVER TRANSPLANTATION; METABOLIC SYNDROME X; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 77952345643     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (77)

1. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421
2. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-359
3. Ford ES, GilesWH, Mokdad AH. Increasing prevalence of the metabolic syndrome among US adults. Diabetes Care 2004;27:2444-2449 (Pubitemid 39281399)
4. Gomila S, Dallongeville J. Epidemiologie du syndrome métabolique en France. Med Nutr 2003;39:89-94.
5. Wilson FW, D'Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005;112:3066-3072
6. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-689 (Pubitemid 32893993)
7. de Simone G, Devereux RB, Chinali M, Best LG, Lee ET, Galloway JM et al. Strong Heart Study InvestigatorsPrognostic impact of metabolic syndrome by different definitions in a population with high prevalence of obesity and diabetes: the Strong Heart Study. Diabetes Care 2007;30:1851-1856
8. Kim CH, Younossi ZM. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med 2008;75:721-728
9. Charlton M. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol 2004;2:1048-1058
10. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123:134-140
11. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999;29:664-669 (Pubitemid 29109578)
12. Ratziu V, Bonyhay L, Di Martino V, Charlotte F, Cavallaro L, SayeghTainturier MH et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002;35:1485-1493
13. Marchesini G, Marzocchi R. Metabolic syndrome and NASH. Clin Liver Dis 2007;11:105-117
14. Björnsson E. The clinical aspects of non-alcoholic fatty liver disease. Minerva Gastroenterol Dietol 2008;54:7-18. (Pubitemid 351518566)
15. Misra VL, Khashab M, Chalasani N. Nonalcoholic fatty liver disease and cardiovascular risk. Curr Gastroenterol Rep 2009;11:50-55
16. Kadayifci A, Tan V, Ursell PC, Merriman RB, Bass NM. Clinical and pathologic risk factors for atherosclerosis in cirrhosis: a comparison between NASH-related cirrhosis and cirrhosis due to other aetiologies. J Hepatol 2008;49:595-599
17. Kadayifci A, Bass NM. Coronary artery disease in NASH-related cirrhosis. J Hepatol 2009;51:963-964
18. Nugent C, Younossi ZM. Evaluation and management of obesityrelated nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2007;4:432-441
19. McCullough AJ. The epidemiology and risk factors for NASH. In: Farrell GC, George J, Hall PM, editors. Fatty liver disease; NASH and related disorders. Bath: Blackwell; 2005. p. 23-37.
20. National Center for Infectious Diseases. Viral Hepatitis C. fact sheet [Internet], [cited 2009 November 9]. Available at: http://www.cdc.gov/hepatitis/ HepatitisC.htm.
21. Angulo P. Nonalcoholic fatty liver disease and liver transplantation. Liver Transpl 2006; 12:523-534
22. Burke A, Lucey MR. Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and orthotopic liver transplantation. Am J Transplant 2004;4:686-693
23. Contos MJ, Cales W, Sterhng RK, Luketic VA, Shiffman ML, Mills AS et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 2001;7:363-373 (Pubitemid 32331542)
24. Ong J, Younossi ZM, Reddy V, Price LL, Gramlich T, Mayes J et al. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl 2001 ;7:797-801. (Pubitemid 32851301)
25. Charlton M, Kasparova P, Weston S, Lindor K, Maor-Kendler Y, Wiesner RH et al. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. liiver Transpl 2001;7:608-614
26. Seo S, Maganti K, Khehra M, Ramsamooj R, Tsodikov A, Bowlus C et al. De novo nonalcoholic fatty liver disease after liver transplantation.Liver Transpl 2007;13:844-847
27. Abdelmalek MF, Diehl AM. De novo nonalcoholic fatty liver disease after liver transplantation. Liver Transpl 2007;13:788-790 (Pubitemid 46939432)
28. Burke A, FitzGerald GA, Lucey MR. A prospective analysis of oxidative stress and liver transplantation. Transplantation 2002;74: 217-221 (Pubitemid 34810289)
29. Mukherjee S, Botha JF, Mukherjee U. Immunosuppression in liver transplantation. Curr Drug Targets 2009;10:557-574
30. Raynard B, Balian A, FaIlik D, Capron F, Bedossa P, Chaput JC et al. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology 2002;35:635-638 (Pubitemid 34183969)
31. PoweU EE, Ali A, Clouston AD, Dixon JL, Lincoln DJ, Purdie DM et al. Steatosis is a co-factor in liver injury in hemochromatosis. Gastroenterology 2005;129:1937-1943
32. Adam R, Hoti E. Liver transplantation: the current situation. Semin Liver Dis 2009;29:3-18.
33. Liver Transplant Waiting List. UNOS database 2009 [Homepage], [cited 2009 November 9]. Available at: http://www.unos.org
34. Imber CJ, St Peter SD, Handa A, Friend PJ. Hepatic steatosis and its relationship to transplantation. Liver Transpl 2002;8:415-423
35. Frongillo F, Avolio AW, Nure E, Mule A, Pepe G, Magalini SC et al. Quantification of degree of steatosis in extended criteria donor grafts with standardized histologic techniques: implications for graft survival. Transplant Proc 2009;41:1268-1272
36. Noujaim HM, de Ville de Goyet J, Montero EF, Ribeiro CM, Capellozzi VL, Crescentini F et al. Expanding postmortem donor pool using steatotic Uver grafts: a new look. Transplantation 2009;87:919-925
37. Trotter JF. Thin chance for fat people to become Living donors. Liver Transpl 2001;7:415-417
38. Tran TT, Changsri C, Shackleton CR, Poordad FF, Nissen NN, Colquhoun S et al. Living donor liver transplantation: histological abnormalities found on liver biopsies of apparently healthy potential donors. J Gastroenterol Hepatol 2006;21:381-383
39. Shields PL, Tang H, Neuberger JM, Gunson BK, McMaster P, Pirenne J. Poor outcome in patients with diabetes mellitus undergoing liver transplantation. Transplantation 1999;68:530-535 (Pubitemid 29416629)
40. John PR, Thuluvath PJ. Outcome of liver transplantation in patients with diabetes mellitus: a case-control study. Hepatology 2001 ;34: 889-895
41. Blanco JJ, Herrero JI, Quiroga J, Sangro B, Gómez-Manero N, Pardo F et al. Liver transplantation in cirrhotic patients with diabetes mellitus: midterm results, survival, and adverse events. Liver Transpl 2001;7:226-233
42. John PR, Thuluvath PJ. Outcome of patients with new-onset diabetes mellitus after liver transplantation compared with those without diabetes mellitus. Liver Transpl 2002;8:708-713
43. Nair S, Cohen DB, Cohen MP, Tan H, Maley W, Thuluvath PJ. Postoperative morbidity, mortality, costs, and long-term survival in severely obese patients undergoing orthotopic liver transplantation. Am J Gastroenterol 2001;96:842-845
44. Hillings JG, Wettergren A, Hyoudo M, Kirkegaard P. Obesity increases mortality in liver transplantation-the Danish experience. Transpl Int 2005;18:1231-1235 (Pubitemid 41726742)
45. Zaydfudim V, Feurer ID, Moore DE, Wisawatapnimit P, Wright JK, Wright Pinson C. The negative effect of pretransplant overweight and obesity on the rate of improvement in physical quality of life after liver transplantation. Surgery 2009;146:174-180
46. Nair S, Verma S, Thuluvath PJ. Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. Hepatology 2002;35:105-109 (Pubitemid 34032549)
47. Ahmed A, Keeffe EB. Current indications and contraindications for liver transplantation. Clin Liver Dis 2007; 11:227-247 (Pubitemid 46990959)
48. Bianchi G, Marchesini G, Marzocchi R, Pinna AD, Zoli M. Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression. Liver Transpl 2008;14:1648-1654
49. Laryea M, Watt KD, Molinari M, Walsh MJ, McAlister VC, Marotta PJ et al. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transpl 2007;13:1109-1114
50. Hanouneh IA, Feldstein AE, McCullough AJ, Miller C, Aucejo F, Yerian L et al. The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation. Liver Transpl 2008;14:1287-1293
51. Tueche SG. Diabetes mellitus after liver transplant new etiologic clues and cornerstones for understanding. Transplant Proc 2003;35:1466-1468
52. Sethi A, Stravitz RT. Review article: medical management of the liver transplant recipient - a primer for non-transplant doctors. Aliment Pharmacol Ther 2007;25:229-245 (Pubitemid 46115393)
53. Pillai AA, Levitsky J. Overview of immunosuppression in liver transplantation. World J Gastroenterol 2009;15:4225-4233
54. Heisel O, Heisel R, Balshaw R, Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant 2004;4:583-595
55. Stewart SF, Hudson M, Talbot D, Manas D, Day CP. Mycophenolate mofetil monotherapy in liver transplantation. Lancet 2001;357: 609-610
56. Munoz SJ, Elghenaidi H. Cardiovascular risk factors after liver transplantation. Liver Transpl 2005;11(1 Suppl 2):52-56
57. Vogt DP, Henderson JM, Carey WD, Barnes D. The long-term survival and causes of death in patients who survive at least 1 year after liver transplantation. Surgery 2002;132:775-780
58. McAvoy NC, Kochar N, McKillop G, Newby DE, Hayes PC. Prevalence of coronary artery calcification in patients undergoing assessment for orthotopic liver transplantation. Liver Transpl 2008;14:1725-1731
59. Roche B, Samuel D. Risk factors for hepatitis C recurrence after liver transplantation. J Viral Hepat 2007; 14(1 Suppl l):89-96. (Pubitemid 47624117)
60. Herrero JI, de la Peña A, Quiroga J, Sangro B, García N, Sola I et al. Risk factors for recurrence of hepatitis C after liver transplantation. Liver Transpl Surg 1998;4:265-270 (Pubitemid 28323744)
61. Charlton M. Natural history of hepatitis C and outcomes following liver transplantation. Clin Liver Dis 2003;7:585-602. (Pubitemid 37093420)
62. Fujioka K. Metabolic syndrome treatment strategies. Pharmacotherapy 2006;26(1 Suppl 2):222-226
63. Kadayifci A, Merriman RB, Bass NM. Medical treatment of nonalcoholic steatohepatitis. Clin Liver Dis 2007; 11:119-140
64. Uygun A, Kadayifci A, Isik AT, Ozgurtas T, Deveci S, Tuzun A et al. Metformin in the treatment of patients with non alcoholic steatohepatitis. Aliment Pharmacol Ther 2004; 19:537-544 (Pubitemid 38387180)
65. Kadayifci A, Merriman RB. Metformin, vitamin E, and diet for patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2006;101:1396-1397
66. Balkau B, Valensi P, Eschwège E, Slama G. A review of the metabolic syndrome. Diabetes Metab 2007;33:405-413
67. Davidson J, Wilkinson A, Dantal J, Dotta F, Haller H, Hernández D et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting, Barcelona, Spain, 19 February 2003. Transplantation 2003;75(Suppl 10):3-24.
68. Bloom RD, Crutchlow MF. Transplant-associated hyperglycemia. Transplant Rev (Orlando) 2008;22:39-51.
69. Boyd ST, Fremming BA. Rimonabant a selective CB1 antagonist Ann Pharmacother 2005;39:684-690
70. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab 2004;30:487-496
71. Toblli JE, Mufioz MC, Cao G, Mella J, Pereyra L, Mastai R. ACE inhibition and ATI receptor blockade prevent fatty liver and fibrosis in obese Zucker rats. Obesity (Silver Spring) 2008;16:770-776
72. Vitale C, Mercuro G, Castiglioni C, Cornoldi A, Tulli A, Fini M et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol 2005;4:6-14.
73. Sloniger JA, Saengsirisuwan V, Diehl CJ, Kim JS, Henriksen EJ. Selective angiotensin II receptor antagonism enhances whole-body insulin sensitivity and muscle glucose transport in hypertensive TG(mREN2)27 rats. Metabolism 2005;54:1659-1668
74. Pershadsingh HA. Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma. Int J Biochem Cell Biol 2006;38:76681.
75. Yokohama S, Yoneda M, Haneda M, Okamoto S, Okada M, Aso K et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004;40:12225.
76. Liado L, Xiol X, Figueras J, Ramos E, Memba R, Serrano T et al. Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: results from a prospective multicenter randomized study. J Hepatol 2006;44:710-716
77. Boillot O, Mayer DA, Boudjema K, Salizzoni M, Gridelli B, Filipponi F et al. Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study. Liver Transpl 2005;11:61-67